T. Rowe Price Investment Management, Inc. Black Diamond Therapeutics, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 10,466,721 shares of BDTX stock, worth $24.8 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
10,466,721
Previous 10,734,389
2.49%
Holding current value
$24.8 Million
Previous $46.7 Million
52.03%
% of portfolio
0.01%
Previous 0.03%
Shares
6 transactions
Others Institutions Holding BDTX
# of Institutions
94Shares Held
47.6MCall Options Held
2.9KPut Options Held
69.4K-
Bellevue Group Ag Kuesnacht, V88.52MShares$20.2 Million0.36% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$13.3 Million0.71% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$10.5 Million0.68% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$7.62 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.41MShares$5.72 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $86.1M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...